| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	UBS analyst Trung Huynh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $194 to $223.
 
																	RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $139 t...
 
																	Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...
 
																	
 
																	
 
																	Balance Sheet, Financial Guidance, and Planned InvestmentsAs of September 30, 2025, Insmed had cash, cash equivalents, and mark...
 
																	Insmed (NASDAQ:INSM) reported quarterly losses of $(1.75) per share which missed the analyst consensus estimate of $(1.38) by 2...
 
																	
 
																	B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $142 to ...